Home > Healthcare > Drug Device Combination > Drug Coated Devices > Drug Device Combination Products Market

Drug Device Combination Products Market Share

Report ID: GMI9674
Published Date: May 2024
Report Format: PDF

Download Free Sample

Drug Device Combination Products Market Share

The global market for drug device combination products is highly competitive, driven by rapid evolution and innovation. With the global market expanding to meet the needs of an aging population and rising chronic disease burdens, companies vie for market share by leveraging technological advancements, regulatory compliance, and strategic collaborations. Established players continuously invest in research and development to enhance their product portfolios, while emerging entrants disrupt traditional models with novel solutions. Regulatory approvals and adherence to quality standards are paramount, driving companies to demonstrate safety, efficacy, and compliance to gain market acceptance. Partnerships and mergers facilitate access to complementary expertise and resources, accelerating product development and market penetration. Additionally, pricing strategies, reimbursement models, and market access policies significantly influence competitive dynamics.

Drug Device Combination Products Market Companies

Key participants operating in the drug device combination products industry include:

Abbott Laboratories
AbbVie, Inc.
Alcon, Inc.
Bausch Health Companies Inc
Baxter International Inc.
Bayer AG
Becton, Dickinson and Company
Boston Scientific Corporation
GlaxoSmithKline plc
Johnson & Johnson
Kaleo, Inc.
Medtronic plc
Novartis AG
SINOMED
Smith & Nephew plc
Teleflex Incorporated
Teva Pharmaceutical Industries Ltd.

Authors: Mariam Faizullabhoy, Gauri Wani

Frequently Asked Questions (FAQ) :

The market size of drug device combination products was reached USD 134 billion in 2023 and is expected to register 7.8% CAGR from 2024 to 2032, owing to the continuous advancements in both drug and medical device technologies driving innovation in drug-device combination products worldwide.

Drug device combination products market from the transdermal delivery systems segment is expected to reach USD 63.2 billion by 2032 due to offering a convenient and non-invasive route of drug administration, which can improve patient compliance.

The U.S. drug device combination products industry is estimated to cross USD 81 billion by 2032 due to technological advancements, regulatory compliance, patient safety concerns, and operational efficiency needs in the region.

Boston Scientific Corporation, GlaxoSmithKline plc, Johnson & Johnson, Kaleo, Inc., Medtronic plc, Novartis AG, SINOMED, Smith & Nephew plc, Teleflex Incorporated, and Teva Pharmaceutical Industries Ltd., are some of the major drug device combination products companies worldwide.